Skip to main content
OpenTrials
Completed

NCT Number: NCT02607358

Non-responders to Antiplatelet Treatment in Acute Ischaemic Stroke)

Determination of frequency of Clopidigrel- and Acetacylicacid-non-responders (HOTPR) in acute ischemic stroke patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Neurologisk afdeling

Roskilde, 4000, Denmark

About this study

Determination of frequency of Clopidigrel- and Acetacylicacid-non-responders (HOTPR) in acute ischemic stroke patients using the VerifyNow system.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Suspected acute ischemic stroke and loading dose of Clopidogrel or Acetacylicacid

Exclusion criteria

  • Previous treatment with platelet inhibitor
  • NOAC or Vitamin K-antagonist treatment
  • Final diagnosis other than Ischemoc stroke or Transitoric ischemic attack

Treatment and study plan

blood sampling for HOTPR-testing

Other

All subjects are tested for responderstatus using the VerifyNow System

Primary outcomes

  1. Responder status

    Time frame: immediately

    Platelet reactivity with PRU measurement

Sponsors and collaborators

Lead sponsor

Zealand University Hospital

Other

Registry information

Official study title

NATIS: Non-responders to Antiplatelet Treatment in Acute Ischaemic Stroke

Acronym: NATIS

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Nov 18, 2015
Registry last updated
Oct 13, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.